30 Years of Evidence

Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study

Jorgo K, Polgar C, Stelczer G, Major T, Gesztesi L, Agoston P | Radiol Oncol | 2021

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy

Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP | Front Oncol | 2021

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China

Zhao X, Ye Y, Yu H, Jiang L, Cheng C, Guo X, Ju X, Zhu X, Zhang H. | J Cancer Res Clin Oncol | 2021

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer

Sarthak Shah, Tamir Sholklapper , Michael Creswell, Abigail Pepin , Jonathan Cantalino, Ryan Andrew Hankins, Simeng Suy, Sean P Collins | Front Oncol | 2021

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China

Chenyang Xu, Xianzhi Zhao, Xiaoping Ju, Yuxin Shen, Min Qu, Yusheng Ye, Xiaoyan Wang, Chunshan Yu, Xu Gao, Huojun Zhang | Front Oncol | 2022

High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial

Fuller DB, Crabtree T, Kane BL, Medbery CA, Pfeffer R, Gray JR, Peddada A, Royce TJ, Chen RC | Front Oncol | 2022

Single fraction radiosurgery for the treatment of renal tumors

Staehler M, Bader M, Schlenker B, Casuscelli J, Karl A, Roosen A, Stief CG, Bex A, Wowra B, Muacevic A | J Urol | 2015

Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma

Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R, Abouassaly R, Welford S, Gulani V, Haaga JR, Machtay M, Ellis RJ | Radiother Oncol | 2015

30 Years of Evidence